Latest Conference Articles

May 18th 2021, 2:00pm

AACR Annual Meeting

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

May 13th 2021, 9:03pm

AACR Annual Meeting

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

May 13th 2021, 8:47pm

AACR Annual Meeting

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

May 12th 2021, 5:21pm

AACR Annual Meeting

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

May 12th 2021, 5:11pm

AACR Annual Meeting

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.

May 8th 2021, 8:01pm

ESMO Breast Cancer Virtual Meeting

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

May 8th 2021, 3:54pm

ESMO Breast Cancer Virtual Meeting

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

May 8th 2021, 10:45am

ESMO Breast Cancer Virtual Meeting

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

May 8th 2021, 10:29am

ESMO Breast Cancer Virtual Meeting

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

May 8th 2021, 1:02am

ESMO Breast Cancer Virtual Meeting

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

May 7th 2021, 10:16pm

ESMO Breast Cancer Virtual Meeting

Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.

May 7th 2021, 9:42pm

ESMO Breast Cancer Virtual Meeting

Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.

May 7th 2021, 9:08pm

ESMO Breast Cancer Virtual Meeting

Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.

May 7th 2021, 5:30pm

ESMO Breast Cancer Virtual Meeting

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

May 7th 2021, 2:09pm

ESMO Breast Cancer Virtual Meeting

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

April 15th 2021, 8:55pm

AACR Annual Meeting

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

April 14th 2021, 11:40pm

AACR Annual Meeting

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

April 14th 2021, 11:31pm

AACR Annual Meeting

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

April 14th 2021, 8:10pm

AACR Annual Meeting

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

April 14th 2021, 1:00pm

AACR Annual Meeting

Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.